Patient Knowledge of GLP-1 Receptor Agonists for Obesity and Exploration of Potential Household-Level Effects in an Urban Health System.

Authors

Leah M Schumacher, Elise Rodrigues, Erin Mraz, Doria Wohler, Astha Rajpal, Sharon J Herring, Daniel J Rubin, Ajay D Rao, Laura Igarabuza, Samantha Flanagan, Daniel Edmundowicz, Resa M Jones

Published in

Obesity science & practice. Volume 12. Issue 5. Pages e70199. Epub Oct 07, 2026.

Abstract

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity management has gained widespread popularity and media attention. However, little is known about patients' knowledge related to GLP-1 RAs (e.g., prescribing indications, side effects), how patients currently learn and wish to learn about GLP-1 RAs, and how GLP-1 RA use may impact weight-related behaviors and attitudes within households (e.g., food purchasing patterns).
This study evaluated these questions among diverse adults recruited from a large, urban health system.
Participants were recruited to complete a brief online questionnaire through flyers posted in several outpatient clinics within a large health system. Recruitment occurred from November 2024 to April 2025. Descriptive statistics were calculated.
Fifty-two patients completed the questionnaire. Overall, 98% of participants had heard at least "a little" about GLP-1 RAs. The conditions participants most commonly believed could benefit from use were obesity (88%), diabetes (75%), and high blood pressure (43%). The side effects they had heard most about were nausea/vomiting (71%), diarrhea (49%), and constipation (47%). Expected amount of weight loss and understanding of GLP-1 RAs' mechanisms of action varied widely. The most common GLP-1 RA information source was commercials/advertisements (73%); however, the most frequently preferred information source was healthcare professionals (87%). In exploratory analyses among patients with current or past GLP-1 RA use and ≥ 1 other household member (n = 12), 75% believed their use impacted adult household members' attention to weight, eating, or exercise; 50% believed GLP-1 RA use impacted child/adolescents household members' attention to these matters; and 42% reported perceived weight loss among household adult(s). All GLP-1 RA users reported changes in their household meal behaviors, and many reported shifts toward more healthful food purchases.
These findings suggest that many patients understand the primary indications for GLP-1 RAs for obesity and common side effects, while also highlighting opportunities for improved decision support. Additional research on a potential "ripple effect" within households using larger samples and more robust methods is warranted.

PMID:
42851870
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.